Changing Role of PET/CT in Cancer Care With a Focus on Radiotherapy
Srinivasan Vijayakumar, Johnny Yang, Mary R Nittala, Alexander E Velazquez, Brandon L Huddleston, Nickhil A Rugnath, Neha Adari, Abhay K Yajurvedi, Abhinav Komanduri, Claus Chunli Yang, William N Duggar, William P Berlin, Richard Duszak, Vani Vijayakumar
Abstract
Positron emission tomography (PET) integrated with computed tomography (CT) has brought revolutionary changes in improving cancer care (CC) for patients. These include improved detection of previously unrecognizable disease, ability to identify oligometastatic status enabling more aggressive treatment strategies when the disease burden is lower, its use in better defining treatment targets in radiotherapy (RT), ability to monitor treatment responses early and thus improve the ability for early interventions of non-responding tumors, and as a prognosticating tool as well as outcome predicting tool. PET/CT has enabled the emergence of new concepts such as radiobiotherapy (RBT), radioimmunotherapy, theranostics, and pharmaco-radiotherapy. This is a rapidly evolving field, and this primer is to help summarize the current status and to give an impetus to developing new ideas, clinical trials, and CC outcome improvements.